Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer

Clinical trials have shown that trastuzumab (H) and pertuzumab (P) combined with chemotherapy as neoadjuvant therapy increased pathological complete response (pCR) rate of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, date in China in the real world a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xiangmin, Zhang, Xiangmei, Zhou, Xinping, Ren, Xiaofei, Ma, Xindi, Zhang, Weifang, Yang, Ruiling, Song, Tao, Liu, Yunjiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543020/
https://www.ncbi.nlm.nih.gov/pubmed/36221359
http://dx.doi.org/10.1097/MD.0000000000030892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543020/
https://www.ncbi.nlm.nih.gov/pubmed/36221359
http://dx.doi.org/10.1097/MD.0000000000030892

Ejemplares similares